Drug Profile
Alteplase biosimilar - Nanogen Biopharmaceutical
Alternative Names: Alteplase - NanogenLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Nanogen Biopharmaceutical Co
- Class Anti-ischaemics; Antihaemorrhagics; Antithrombotics; Cardiovascular therapies; Plasminogen activator enzymes; Recombinant proteins; Thrombolytics; Vascular disorder therapies
- Mechanism of Action Plasminogen activator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Myocardial infarction; Pulmonary embolism; Stroke
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for research development in Myocardial-infarction in Vietnam (IV, Injection)
- 28 Apr 2018 No recent reports of development identified for research development in Pulmonary-embolism in Vietnam (IV, Injection)
- 28 Apr 2018 No recent reports of development identified for research development in Stroke in Vietnam (IV, Injection)